Looking for something?
Michele Carrer, Ph.D.
Executive Director, Department of Neurology
Ionis Pharmaceuticals, Carlsbad, CA
“Conjugation to a transferrin receptor 1-binding Bicycle peptide enhances ASO and siRNA potency in skeletal and cardiac muscles”
https://doi.org/10.1093/nar/gkaf270
Biography:
Michele Carrer, Ph.D., is an Executive Director in the Department of Neurology at Ionis Pharmaceuticals in Carlsbad, CA. The research led by Dr. Carrer and his team focuses on developing RNA-targeted medicines to address the root cause of skeletal muscle diseases and on advancing ligand-conjugation platforms to efficiently deliver antisense therapeutics to skeletal and cardiac muscle.
In 2021, Ionis Pharmaceuticals and Bicycle Therapeutics established a partnership to advance muscle-targeted oligonucleotide delivery approaches. The joint efforts of Dr. Carrer, his colleagues across multiple departments at Ionis — including co-first author Dr. Michael Østergaard — and partners at Bicycle Therapeutics culminated in the publication of the article entitled “Conjugation to a transferrin receptor 1-binding Bicycle peptide enhances ASO and siRNA potency in skeletal and cardiac muscles” in Nucleic Acids Research. This work was recognized with the Oligonucleotide Therapeutics Society Paper of the Year Award in 2025.
Dr. Carrer earned his Ph.D. in Genetics and Development from the University of Texas Southwestern Medical Center at Dallas under the mentorship of Dr. Eric N. Olson and completed his postdoctoral training at the Genomics Institute of the Novartis Research Foundation.
